Jay Dong – General Manager (China and APAC) & Vice President…
Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the…
Address: 27 Chao Qian Road,
Changping District Beijing, 102200, China
Tel: -69722764
Web: http://www.zhongsheng.com.cn/en/index.asp
BioSino Bio-technology and Science Inc, founded in 1988, is a leading high-technology enterprise whose major national controlling stakeholders comprise the Chinese Academy of Sciences, Beijing Municipal Government and Shanghai Municipal Government. Biosino has already become the largest manufacturer of IVD reagents in China after 20 years development.BioSino successfully finished IPO in GEM of Hong Kong Stock in 2006, symbolizing that she has marched away for her globalization, grouping and synthesis of running both products and capital. Now, Biosino has 90 IVD products, more than 200 formats including biochemistry diagnostic reagents, immunology diagnostic reagents and rapid tests. Lots of our products have got CE mark and more products are in the process of application. Now, BioSino has developed over 600 distributors and retailers over the country, occupy 75% of the Chinese market. Moreover, we have exported to over 20 countries from Southeast Asia, Middle-east, North Africa, and South America.In order to ensure consistently high quality, BioSino built a new GMP standard plant (11000m2) and established a microcomputer-controlled automated production line to achieve a completely sealed, sterile, temperature and humidity controlled environment. At the same time, meticulous and experienced employees are hired for quality control, technological safeguards and production operations. Each step is strictly in accordance with the requirements of quality control standards ISO9001:2000 and ISO13485:2003.BioSino has a professional after sales service team comprising experts in the field of biochemistry, immunology, pharmacy and medicine. We provide on-the-spot technological support and service to our customers, teach them how to use our products and resolve problems they meet. Our commitment is to provide the best service at the first moment.Looking into the future, BioSino will keep on developing new products to meet the demands of international markets. Our aim is to become a leading diagnostic manufacturer in the world and create a better future together with our partners and customers.
Bio Chemistry Reagents
Immunology Reagents
Rapid Testing Diagnostics
Diagnostic Instruments
Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the…
Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is responsible for bringing“International Rare Disease Day” to…
What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging markets? Eric Bouteiller and Simon Wan of Cornerstone…
Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish…
Dr John Gong, CEO of 3D Medicines, shares the company’s ‘3D – diagnostics, data, and drug development’ approach to cancer precision medicine; his philosophy of putting patient needs at the…
China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies” scandal. The committee will not be limited to overseeing gene editing…
Yuichi Yomasu, president of Daiichi Sankyo China, shares his first impressions of the dynamic but complex Chinese market since he assumed position ten months ago; the strategic importance of the…
Harbour BioMed is a fast-growing global biotech company with facilities in Rotterdam, Boston and Shanghai. The company is laser-focused on developing both proprietary and in-licensed immunological therapies using their state-of-the-art…
Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic…
Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic…
While others have failed during the last 30 years, Hua Medicine has finally succeeded in developing a breakthrough diabetes treatment controlling blood glucose levels by taking a novel approach and…
Hong Chow, general manager of Roche Pharma China, shares Roche China’s incredible milestones over the past few years, including four pivotal oncology drugs listed on the National Reimbursement Drug List…
See our Cookie Privacy Policy Here
